<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049083</url>
  </required_header>
  <id_info>
    <org_study_id>SHR2554-I-108</org_study_id>
    <nct_id>NCT05049083</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Different Specifications of SHR2554 Tablets in Healthy Adult Subjects</brief_title>
  <official_title>A Single-centre, Single-dose, Random, Open, Two-period, Cross-over Relative Bioavailability Study of Different Specifications of SHR2554 Tablets in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the relative bioavailability, pharmacokinetics and&#xD;
      safety of different tablet specifications of SHR2554 in healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 23, 2021</start_date>
  <completion_date type="Anticipated">October 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A single-centre, single-dose, random, open, two-period, cross-over relative bioavailability study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events/serious adverse events</measure>
    <time_frame>from ICF signing date to approximate day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>New Specification SHR2554 tablet、Former Specification SHR2554 tablet</intervention_name>
    <description>New Specification, 350 mg SHR2554 tablets on study day 1 - Former Specification, 350 mg SHR2554 tablets on study day 8</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Former Specification SHR2554 tablet、New Specification SHR2554 tablet</intervention_name>
    <description>Former Specification, 350 mg SHR2554 tablets on study day 1 - New Specification, 350 mg SHR2554 tablets on study day 8</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written informed consent and willing and able to participate this&#xD;
             research.&#xD;
&#xD;
          2. Health female or male aged 18 to 45 at date of informed consent.&#xD;
&#xD;
          3. Weighing ≥45 kg for female and ≥50 kg for male, body mass index between 19.0 and 26.0&#xD;
             kg/m2.&#xD;
&#xD;
          4. Normal or abnormal but with no clinically significant in physical examination, vital&#xD;
             signs, laboratory tests (haematology, clinical chemistry, urinalysis, coagulation&#xD;
             function), 12 lead ECG, abdominal B ultrasound and CT.&#xD;
&#xD;
          5. Participants should have no fertility plan and take effective contraceptive measures&#xD;
             voluntarily from 2 weeks prior dose (for female) until 3 months after the last dose&#xD;
             (for both female and male), and have no sperm or ovum donation plan; for fertile women&#xD;
             the serum HCG test must be negative within Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with chronic or serious disease history or current disease in respiratory&#xD;
             system, circulatory system, digestive system, urinary system, blood system, endocrine&#xD;
             system, immune system, nervous system, mental system, etc., and are not suitable for&#xD;
             enrollment as assessed by the investigator.&#xD;
&#xD;
          2. Surgery history that may affect drug absorption in gastrointestinal tract (including&#xD;
             gastrectomy, enterectomy, stomach reduction surgery, etc.).&#xD;
&#xD;
          3. Surgery history within 6 months prior to screening or surgery plans during the study.&#xD;
&#xD;
          4. Plasma donation or blood loss greater than 400 mL or transfusion within 3 months prior&#xD;
             to screening, or greater than 200 mL within 1 month prior to screening.&#xD;
&#xD;
          5. Positive results on screening tests for HBsAg and/or HCsAg and/or HIV and/or syphilis.&#xD;
&#xD;
          6. History of drug abuse or positive results of drug tests.&#xD;
&#xD;
          7. Alcohol abuse or smokers (≥14 units of alcohol per week within 6 months prior to&#xD;
             screening: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine; ≥5&#xD;
             cigarettes per day), or unable to stop drinking or smoking during the study; positive&#xD;
             results on screening tests for alcohol or nicotine.&#xD;
&#xD;
          8. History of allergy/hypersensitivity (allergy/hypersensitivity to more than two&#xD;
             substances), or are not suitable for enrollment as assessed by the investigator.&#xD;
&#xD;
          9. Swallowing resistance or obstacles that affect drug absorption.&#xD;
&#xD;
         10. Participation in any other clinical study that included drug treatment within 3 months&#xD;
             prior to first SHR2554 dose.&#xD;
&#xD;
         11. Administration of any CYP3A4 inducers or inhibitors within 4 weeks prior to first&#xD;
             SHR2554 dose.&#xD;
&#xD;
         12. Administration of any prescription/non-prescription medicine or traditional Chinese&#xD;
             medicine or dietary supplement within 2 weeks prior to first SHR2554 dose.&#xD;
&#xD;
         13. Administration of food or drinks that containing grapefruit, methylxanthine or alcohol&#xD;
             within 72 hours prior to first SHR2554 dose; Strenuous exercise.&#xD;
&#xD;
         14. Participants who have special dietary requirements and cannot accept a unified diet.&#xD;
&#xD;
         15. Any factors that affect drug absorption, distribution, metabolism or excretion.&#xD;
&#xD;
         16. Lactating women.&#xD;
&#xD;
         17. History of fainting needles or blood; difficulty in blood collection or intolerance of&#xD;
             venipuncture blood collection.&#xD;
&#xD;
         18. Any factors are not suitable for enrollment as assessed by the investigator or&#xD;
             participants withdrew from the study for their own reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuya Wang</last_name>
    <phone>13918749176</phone>
    <email>yuya.wang@hengrui.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

